These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9933579)

  • 1. Protein kinase Ciota activity is necessary for Bcr-Abl-mediated resistance to drug-induced apoptosis.
    Jamieson L; Carpenter L; Biden TJ; Fields AP
    J Biol Chem; 1999 Feb; 274(7):3927-30. PubMed ID: 9933579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcr-Abl regulates protein kinase Ciota (PKCiota) transcription via an Elk1 site in the PKCiota promoter.
    Gustafson WC; Ray S; Jamieson L; Thompson EA; Brasier AR; Fields AP
    J Biol Chem; 2004 Mar; 279(10):9400-8. PubMed ID: 14670960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NF-kappaB/RelA transactivation is required for atypical protein kinase C iota-mediated cell survival.
    Lu Y; Jamieson L; Brasier AR; Fields AP
    Oncogene; 2001 Aug; 20(35):4777-92. PubMed ID: 11521190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
    Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors.
    Bhatia R; Munthe HA; Verfaillie CM
    Leukemia; 1998 Nov; 12(11):1708-17. PubMed ID: 9823945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro.
    Svingen PA; Tefferi A; Kottke TJ; Kaur G; Narayanan VL; Sausville EA; Kaufmann SH
    Clin Cancer Res; 2000 Jan; 6(1):237-49. PubMed ID: 10656455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic mechanisms of p210BCR-ABL signaling: induction of heat shock protein 70 through the GATA response element confers resistance to paclitaxel-induced apoptosis.
    Ray S; Lu Y; Kaufmann SH; Gustafson WC; Karp JE; Boldogh I; Fields AP; Brasier AR
    J Biol Chem; 2004 Aug; 279(34):35604-15. PubMed ID: 15155749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells.
    Dou QP; McGuire TF; Peng Y; An B
    J Pharmacol Exp Ther; 1999 May; 289(2):781-90. PubMed ID: 10215653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
    Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
    Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
    Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia.
    Kaur G; Gazit A; Levitzki A; Stowe E; Cooney DA; Sausville EA
    Anticancer Drugs; 1994 Apr; 5(2):213-22. PubMed ID: 8049505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cells.
    Urbano A; Gorgun G; Foss F
    Biochem Pharmacol; 2002 Feb; 63(4):689-92. PubMed ID: 11992636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Jak2 is involved in c-Myc induction by Bcr-Abl.
    Xie S; Lin H; Sun T; Arlinghaus RB
    Oncogene; 2002 Oct; 21(47):7137-46. PubMed ID: 12370803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.
    Motiwala T; Majumder S; Ghoshal K; Kutay H; Datta J; Roy S; Lucas DM; Jacob ST
    J Biol Chem; 2009 Jan; 284(1):455-464. PubMed ID: 18997174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
    Huang M; Dorsey JF; Epling-Burnette PK; Nimmanapalli R; Landowski TH; Mora LB; Niu G; Sinibaldi D; Bai F; Kraker A; Yu H; Moscinski L; Wei S; Djeu J; Dalton WS; Bhalla K; Loughran TP; Wu J; Jove R
    Oncogene; 2002 Dec; 21(57):8804-16. PubMed ID: 12483533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571.
    Yu C; Dai Y; Dent P; Grant S
    Cancer Biol Ther; 2002; 1(6):674-82. PubMed ID: 12642693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
    Oetzel C; Jonuleit T; Götz A; van der Kuip H; Michels H; Duyster J; Hallek M; Aulitzky WE
    Clin Cancer Res; 2000 May; 6(5):1958-68. PubMed ID: 10815921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
    Cheong JW; Chong SY; Kim JY; Eom JI; Jeung HK; Maeng HY; Lee ST; Min YH
    Clin Cancer Res; 2003 Oct; 9(13):5018-27. PubMed ID: 14581377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents.
    Stiewe T; Parssanedjad K; Esche H; Opalka B; Pützer BM
    Cancer Res; 2000 Jul; 60(14):3957-64. PubMed ID: 10919674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
    Yu C; Rahmani M; Almenara J; Subler M; Krystal G; Conrad D; Varticovski L; Dent P; Grant S
    Cancer Res; 2003 May; 63(9):2118-26. PubMed ID: 12727828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.